Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
A flat illustration of a proxy drug molecule interacting with a target protein in a laboratory setting.

Jul 28, 2026

Insights from SLAS Europe 2026 - SelectScience interview

At the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), researchers are pioneering the integration of academic research and industrial applications in drug discovery. Their focus is on developing proximity-inducing drugs, which differ from traditional small molecules by modulating protein interactions rather than merely inhibiting protein functions.Proximity-inducing drugs, or proxy drugs, operate by binding to a target protein and recruiting another protein via mechanism
A minimalist illustration of a pill and bacteria in flat design.

Jul 27, 2026

Antares project launches: AI aims to accelerate search for new antibacterials

The Antares project, a collaborative initiative funded by the German Federal Ministry of Research, Technology and Space, aims to leverage artificial intelligence in the search for new antibiotics. This public-private partnership involves key players like the Fraunhofer ITMP, Helmholtz Centre for Infection Research, and Enamine Deutschland, focusing on developing effective treatments for drug-resistant infections.The project employs AI models trained on publicly accessible datasets to streamline
A minimalist representation of a bispecific antibody targeting tumor antigens.

Jul 27, 2026

VERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens

VERAXA Biotech has announced the advancement of its bispecific antibody drug conjugate (bsADC) program, VXA-222, following a successful milestone in collaboration with OmniAb. This innovative therapy targets two distinct tumor antigens simultaneously, utilizing an “AND-gate” mechanism.VXA-222 represents a significant step forward in cancer treatment, addressing solid tumors that currently have high unmet medical needs. The collaboration leverages OmniAb’s advanced antibody discovery technologies
A minimalist illustration of a molecule and a contract representing biotech growth.

Jul 24, 2026

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

MindWalk Holdings Corp. has reported significant financial growth, showcasing the tangible impact of its AI-driven drug discovery platform.In its recent fiscal report, MindWalk Holdings, a company specializing in AI applications for drug discovery, announced a 46% revenue increase, reaching C$15.6 million. This surge is coupled with a notable reduction in net losses, which fell by over 50% to C$13.9 million. The company also achieved a critical milestone by signing its first two recurring enterp
Minimalist illustration of an antibody structure

Jul 23, 2026

Creative Biolabs launches end-to-end AI-driven antibody solutions

Creative Biolabs has introduced a comprehensive AI-driven platform designed to revolutionize the antibody discovery process in biopharmaceuticals, significantly reducing timelines for early-stage development.This innovative framework integrates generative deep-learning models with high-throughput experimental workflows, addressing common structural challenges in drug development. Traditional antibody discovery often suffers from high attrition rates due to unfavorable biophysical properties and
A glass vial with a colorful drug compound in a lab setting

Jul 23, 2026

Insilico Medicine and Bora Pharmaceuticals sign strategic partnership worth up to $2.5 billion

Insilico Medicine has formed a strategic partnership with Bora Pharmaceuticals, potentially worth up to $2.5 billion, to enhance AI-driven drug discovery and pharmaceutical development.This collaboration aims to merge Insilico's Pharma.AI platform with Bora's extensive expertise in drug development, manufacturing, and commercialization. By doing so, the companies intend to create a more streamlined process for bringing innovative therapies to market, significantly reducing the time from drug dis
A minimalist illustration of a test tube with bubbles, symbolizing chemical reactions in drug discovery.

Jul 23, 2026

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

MindWalk Holdings Corp. has reported a significant 46% increase in revenue, signaling a successful transition toward a recurring revenue model in the AI-driven drug discovery sector.In its latest fiscal year results, MindWalk Holdings Corp. (NASDAQ: HYFT) showcased a remarkable shift in its business approach, reporting a revenue increase to C$15.6 million, up from C$10.6 million the previous year. This growth coincided with a substantial reduction in net loss, which halved to C$13.9 million. The
A glass vial containing a drug compound on a lab bench with equipment in the background.

Jul 22, 2026

Cheiron Raises $8M to Launch AI-Native the Operating System for Drug Programs

Cheiron, an AI-native platform in the life sciences sector, has successfully raised $8 million in seed funding, with notable investors including Menlo Ventures and high-profile figures from the biotech and tech industries.The platform aims to transform the fragmented landscape of drug development by consolidating various data sources—such as clinical, regulatory, and commercial information—into a single, auditable operating system. This interconnected approach is designed to streamline the drug
Molecular model in a laboratory setting

Jul 22, 2026

R&D Is Investing in AI, Just Not Where It Matters Most

The pharmaceutical industry is poised to invest $25 billion in AI by 2030, driven by the promise of enhanced drug discovery and decision-making. However, a concerning trend is emerging: adoption rates for AI in critical areas of drug discovery, such as generative design and biomarker analysis, are significantly lagging. A primary reason for this disconnect is the fragmented data environment that underpins AI applications, rather than the technology itself.Despite substantial financial commitment
A server rack in a data center with glowing lights and cables

Jul 21, 2026

Pharma Giant and NVIDIA Join Forces to Build the Most Powerful AI Supercomputer Yet

Bristol Myers Squibb (BMS) and NVIDIA are collaborating to create a groundbreaking AI supercomputer aimed at revolutionizing drug development in the pharmaceutical industry.The partnership is set to launch the supercomputer in January 2027, with infrastructure support from Equinix. This initiative reflects a broader trend within the industry as companies increasingly adopt artificial intelligence to enhance drug discovery processes and reduce operational costs. BMS researchers will utilize NVIDI
Petri dish with cell cultures and research notes in a lab

Jul 21, 2026

Sightera Bio secures €3 million for AI drug discovery platform

Sightera Biosciences has successfully secured €3 million in pre-seed funding to enhance its AI-driven drug discovery platform, focusing on oncology and fibrosis.The Antwerp-based startup plans to utilize this funding to expand its team, advance its technology, and move its lead oncology program toward preclinical candidate selection. Additionally, Sightera aims to strengthen partnerships with pharmaceutical and biotech firms. The funding round was led by Entourage, Anacura, and QBIC, highlightin
Silhouette of a supercomputer with GPUs

Jul 21, 2026

BMS claims pharma's most powerful AI supercomputer. How it stacks up to Lilly's and Roche's.

Bristol Myers Squibb (BMS) has announced the acquisition of an NVIDIA DGX SuperPOD, which it claims is the most powerful and energy-efficient AI supercomputer in life sciences. This announcement comes after Eli Lilly and Roche made their own claims about leading AI supercomputing capabilities within the industry.BMS's new system is an expansion of its existing infrastructure, which has been in operation since 2024. The new setup will integrate eight racks of Vera Rubin NVL72 systems, featuring 5